Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
[email protected]+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

Author Archives: PharmAust

Appendix 4E & Preliminary Final Report

News & Announcements 2020By PharmAust31/08/2020

200831_Appendix 4E & Preliminary Final Report

Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells

News & Announcements 2020By PharmAust25/08/2020

200825_Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells

July 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust01/08/2020

200731_top20shareholders

28 July Appendix 4C and Quarterly Update

News & Announcements 2020By PharmAust28/07/2020

200728_Appendix4CandQuarterlyUpdate

13 July, Final Report delivered under Option Agreement

News & Announcements 2020By PharmAust13/07/2020

200713_Final Report Option Agreement

Epichem Corporate Presentation July 2020

Investor Presentations 2020By PharmAust02/07/2020

Epichem Pty Ltd Corporate Presentation 2020 Final

PharmAust Shareholder Update Presentation June 2020

Investor Presentations 2020By PharmAust02/07/2020

PAA PRESENTATION JUN 2020 RA FINAL (1)

June 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust01/07/2020

200701_topShareholders

JP Equity Partners – Broker Analyst Report – July 2020

News & Announcements 2020, Research Notes 2020By PharmAust30/06/2020

PAA Research Report – June 2020

24 June, Shareholder Update

News & Announcements 2020By PharmAust24/06/2020

200624_ShareholderUpdate

←1
234567891011121314
…1516171819…
2021222324252627282930313233343536373839404142434445464748495051
52→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
24 Jun

📸 Highlights from the MND Australia Global Day Event at Parliament House!

We teamed up with FightMND to raise awareness and fight for a future free of Motor Neurone Disease. 💙

#MNDAustralia #FightMND #MNDGlobalDay

Reply on Twitter 1805134834358210569 Retweet on Twitter 1805134834358210569 2 Like on Twitter 1805134834358210569 12 Twitter 1805134834358210569
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
21 Jun

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
#ASX @PharmAust

Reply on Twitter 1803984607676654065 Retweet on Twitter 1803984607676654065 1 Like on Twitter 1803984607676654065 3 Twitter 1803984607676654065
pharmaust PharmAust @pharmaust ·
21 Jun

Exciting news for our investors! 🎉 Check out the details of our latest capital raise here: https://investorhub.pharmaust.com/investment-offer/32. Thank you for your continued support! 🌟 #PharmAust

Reply on Twitter 1804030728956711230 Retweet on Twitter 1804030728956711230 2 Like on Twitter 1804030728956711230 7 Twitter 1804030728956711230
Load More

Copyright © 2025 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top